Publications by authors named "Zheqing Liu"
Immunotherapy
October 2024
Article Synopsis
- * After conservative treatment for cholecystitis, the patient switched to zimberelimab, a different PD-1 antibody, and completed 37 cycles without experiencing further immune-related side effects.
- * Remarkably, the patient has remained in complete remission for 28.8 months, suggesting that switching PD-1 therapies might be a safe option after managing adverse effects from another PD-1 treatment.
